ChatGPT

Restated Rules

- **Budget Discipline:** Only use the available portfolio cash; no additional capital. Track cash precisely after each trade.
- **Execution Limits:** Trade in full share increments only. No use of options, short selling, margin, or leverage – long equity positions only.
- **Universe Focus:** Emphasize U.S. micro-cap stocks (market cap under ~$300M) unless otherwise justified. Ensure adequate trading liquidity (reasonable volume, tight spreads) to minimize slippage.
- **Risk Control:** Adhere to stop-loss levels and prudent position sizing. Immediately flag any concentration or stop-loss violations. Maintain stop-loss orders on all positions to limit downside.
- **Weekly Cadence:** This is the in-depth weekly review. We have full discretion to adjust positions – add new names, or exit/trim/add to existing positions – in pursuit of improved risk-adjusted returns. All decisions and orders are to be executed in this week's trading window.
- **Complete Autonomy:** Act in the portfolio's best interest to generate alpha, within these rules and constraints.

Research Scope

In this deep-dive, I examined each current holding's recent performance, news, and fundamentals using up-to-date sources. I analyzed recent financial results, regulatory announcements, and market data for each company. I also scanned for new micro-cap candidates with upcoming catalysts or compelling valuations. Key sources included company press releases, financial news outlets, and market data services (Yahoo Finance, Finviz, etc.), ensuring information reflects the latest developments (mid Q3 2025). All data points and news are cited accordingly. The goal was to assess whether to keep, adjust, or replace each holding and to identify any new opportunities that fit our strategy.

Current Portfolio Assessment

ABEO (Abeona Therapeutics) – **Role:** High-conviction biotech holding (gene therapy). **Entry Date/Price:** Added Week 5 at $5.77; now ~$6.9. **Cost Basis:** $23.08 total. **Current Stop:** $6.20 (above cost, locks in profit). **Conviction: High.** Abeona received FDA approval in April 2025 for its first-in-class gene therapy ZEVASKYN (for RDEB, a rare pediatric skin disease) [1] [2]. The commercial launch is underway with strong early demand and payer coverage in place [3] [4]. The company's cash position is extremely robust after selling a Priority Review Voucher for $155M, boosting cash to ~$226M as of Q2 (funding 2+ years of operations) [5] [6]. Analysts project significant upside (price targets $16–21) given Abeona's ~$350M market cap and ~$226M cash on hand [7] [8]. **Status: KEEP/ADD.** The thesis is intact – Abeona is transitioning to a revenue-generating company with a potentially transformative therapy. Upside remains as the launch progresses and profitability is forecast by 1H 2026 [5]. We will maintain our position (and consider adding modestly) due to high conviction and positive momentum. Stop-loss is set just below recent support (mid-$6s) to protect gains while allowing volatility.

ATYR (aTyr Pharma) – **Role:** Core biotech position (orphan lung disease therapy). **Entry:** Week 4 at ~$5.21; now ~$5.61. **Cost Basis:** $62.48. **Stop:** $4.22 (~20% below current). **Conviction: High.** aTyr's lead drug (efzofitimod) for pulmonary sarcoidosis completed Phase 3 patient visits in July [9] [10]. Top-line data are anticipated within the next few months, a major catalyst that "could push shares through the roof" [11] [12]. The company was also added to several Russell equity indices in June [13] [14], increasing its visibility and liquidity. Recent Q2 results showed stable financials (net loss slightly widened, but loss per share improved year-on-year) [15]. Importantly, aTyr is well-funded (no near-term cash crunch indicated) and the stock has strong analyst support (consensus *Strong Buy*, 12-month PT ~$23) [16] [17]. **Status: KEEP.** We maintain a high conviction as Phase 3 data approach. The Russell index inclusion and a 48% YTD rise (as of late August) reflect growing optimism [18]. However, the position is large (~50% of portfolio). We will **hold** for now given the imminent catalyst, but we note the concentration risk. (No immediate trim since upside potential is significant, but we will monitor position size closely.) The stop-loss will be raised from $4.22 to **$4.60** to reduce downside risk, while still giving the stock room to fluctuate in the pre-data period.

AXGN (Axogen Inc.) – **Role:** Medical device/biotech hybrid (peripheral nerve repair). **Entry:** Week 6 at $14.96; now ~$15.7 (slightly above cost). **Cost Basis:** $29.92. **Stop:** $13.00. **Conviction: Moderate.** Axogen's fundamentals are improving – Q2 revenue grew +18% YoY to $56.7M, and the company turned a small net profit of $0.6M (vs. loss prior) [19]. However, a key regulatory catalyst was delayed: the FDA extended the review of Axogen's Biologics License Application for its Avance Nerve Graft by three months (new PDUFA date Dec 5, 2025) [20]. This extension (due to a "major amendment") caused a >15% drop in the stock in late August [21]. While not a rejection, it injects uncertainty and pushes the catalyst beyond our time horizon. The stock had surged ~76% in the two months prior to the delay on approval hopes, and then "plummeted" on the news [22]. With shares now off their highs (52-week high $21, current ~$16 [23]), the near-term upside may be limited until FDA resolution. **Status: EXIT.** Given the lack of near-term catalyst (no FDA decision until December) and the stock's relatively high market cap (~$715M [23]) now above our typical micro-cap range, we will **sell Axogen**. This frees up capital for more promising opportunities with nearer catalysts. We also avoid the risk of any further FDA-related surprises. Axogen remains a good company fundamentally, and we may revisit it once the regulatory outcome is clearer, but for this 6-month experiment, we prefer to reallocate to higher-upside ideas.

FBIO (Fortress Biotech) – **Role:** Speculative biotech holding company. **Entry:** Week 8 at $2.85; now $3.71 (~30% gain on initial position). **Cost Basis:** $2.85 (1 share). **Stop:** $2.00 (wide, ~46% below current). **Conviction: Moderate-High (short-term catalyst play).** Fortress is a unique biotech aggregator with multiple shots on goal. The stock just surged +30% on Sep 5 on heavy volume (6.3M shares) [24] driven by optimism for an upcoming FDA decision. One of Fortress's partner companies has a treatment for Menkes disease (a rare pediatric disorder) with a PDUFA date of **September 30, 2025** [25]. Investors are "closely watching" this event, expecting potential approval to significantly boost Fortress's value [26]. The DoD also recently contracted Fortress (via a subsidiary) for broad-spectrum antivirals, providing non-dilutive funding [27] [28]. Fortress's market cap is still only about $110M [29], and analysts' 2025 price predictions run as high as $9.50 [30] (implying substantial upside if even a couple of its pipeline bets pay off). **Status: KEEP/ADD.** We will hold Fortress through the Menkes decision catalyst. The risk is binary (approval could spike the stock, a rejection could tank it). Our stop at $2.00 is largely symbolic (a negative outcome could gap the price below $2). Given our small initial size, we will **add modestly** to increase exposure to the catalyst while keeping position size reasonable. Liquidity is ample and recent momentum is strong. We judge the risk/reward favorable into 9/30.

Candidate Set

After scanning for new opportunities, two candidates stood out:

- **FDMT (4D Molecular Therapeutics)** – Gene therapy innovator trading around ~$7 (mkt cap ~$300M). **Thesis:** The company recently announced positive clinical results for its intravitreal gene therapy: strong, dose-dependent efficacy with *no intraocular inflammation* [31] – a key differentiator vs competitors. This led to a surge off summer lows, and analysts have a $25 price target on the stock [32]. With a rich pipeline in ophthalmology and cardiology and about $200M+ in cash (as of Q2) to fund trials, FDMT appears undervalued. **Catalyst:** Additional Phase 1/2 data updates or partnership news in coming quarters; general biotech sentiment improvement. **Liquidity:** Moderate – ~0.7M shares/day recently [33], sufficient for our small trades. *Note:* still pre-revenue, so high volatility is expected (recent 10% single-day swings). We find the risk/reward attractive after the positive data readout.

- **OMER (Omeros Corp)** – Late-stage biotech (~$4.17/share). **Thesis:** Omeros has an FDA-ready drug (narsoplimab) for a rare blood disorder and a lucrative renal disease drug partnership. The stock is down ~85% from peaks, leaving a market cap around $280M [34]. It has limited dilution recently (≈58M shares outstanding) [35] [36] and some ongoing royalty revenue from a product sale. **Catalyst:** A potential FDA re-filing or EU approval for narsoplimab (timeline uncertain), or deal announcements. **Liquidity:** Fair – ~0.55M shares/day [37]. *However*, we note significant downside risks: high debt (enterprise value ~$636M) [38] and no clear near-term FDA catalyst (after a past setback). OMER appears undervalued on paper, but without a defined upcoming trigger in our 6-month window, it may remain a "value trap." We **considered but decided against** initiating OMER due to the unclear catalyst timing and its higher risk profile relative to alternatives.

Portfolio Actions

Keep ABEO – *Rationale:* Abeona's story (first gene therapy for RDEB) is playing out well, with FDA approval secured and launch execution underway [1] [2]. The stock has appreciated ~20% since our entry, but substantial upside remains (analyst PTs triple current price) [7]. With $200M+ cash and expected profitability by next year [5] [6], downside is limited. We'll maintain our position, possibly adding on any pullbacks. Stop-loss $6.20 is retained to protect profits.

Keep ATYR – *Rationale:* aTyr Pharma continues to be a high-conviction holding ahead of Phase 3 trial results. The stock has momentum (up ~8% from cost) and strong fundamentals: added to key indexes [13] and sufficient cash runway. The upcoming Efzofitimod data for pulmonary sarcoidosis is a transformative catalyst. We are mindful of its outsized weight (>50%); nevertheless, the risk/reward justifies holding the full position into data. Stop is tightened to $4.60 to mitigate downside.

Exit AXGN – *Rationale:* We will sell Axogen. While we believe in its long-term prospects (growing revenue, near profitability), the key catalyst (FDA approval of Avance Nerve Graft) has been delayed to Dec 2025 [20], beyond our experimental window. Without near-term drivers, the stock may stagnate or drift. Additionally, Axogen's market cap has grown (~$715M) [23], moving it out of our micro-cap focus. We prefer to reallocate the ~$30+ proceeds into opportunities with more imminent upside.

Add to FBIO – *Rationale:* Fortress Biotech is approaching a critical binary event (Sept 30 FDA decision). The recent 30% surge suggests growing investor confidence [25]. Given our small initial stake, we'll add a few shares to bring FBIO to a modest but meaningful position (~8–9% of portfolio). This increases our exposure to a potentially significant catalyst-driven gain. We remain cautious (position will still be small) due to event risk, and will keep the wide $2.00 stop.

Initiate FDMT – *Rationale:* We will initiate a new position in 4D Molecular Therapeutics. The stock offers a compelling catalyst-driven setup: it jumped ~10% on 9/5 to ~$7.27 [33] [39] after announcing encouraging trial results (durable treatment effect with no safety red flags). We view this as an inflection point for market sentiment on FDMT. The company's novel capsid technologies and multiple shots on goal (Wet AMD, X-linked retinitis pigmentosa, etc.) give it multi-bagger potential if upcoming data remain positive. With shares still near multi-month lows (despite the recent bounce) and sufficient liquidity, we find the entry attractive. A stop around $5.75 will limit risk (~20% downside). Position size will be moderate (~11% of portfolio) to reflect the higher volatility and early-stage nature.

Exact Orders

1. Sell AXGN (Axogen Inc.) – *Exit entire position*
- **Action:** Sell
- **Ticker:** AXGN
- **Shares:** 2 (full holding)
- **Order Type:** Limit (DAY)
- **Limit Price:** $15.50
- **Intended Execution Date:** 2025-09-08 (next trading day)
- **Stop-Loss:** N/A (exit order)
- **Special Instructions:** Sell at market open if price ≥ $15.50; allow partial fill if necessary.
- **Rationale:** Axogen's catalyst is delayed (FDA decision pushed to Dec) [20]. Capital can be better utilized in nearer-term opportunities. Locking in a slight gain here and freeing ~$31 cash for redeployment.

2. Buy additional FBIO (Fortress Biotech) – *Increase position for catalyst*
- **Action:** Buy
- **Ticker:** FBIO
- **Shares:** 2 (adding to current 1 share, new total 3 shares)
- **Order Type:** Limit (DAY)
- **Limit Price:** $3.80
- **Intended Execution Date:** 2025-09-08
- **Stop-Loss:** $2.00 (existing stop; will apply to entire 3-share position)
- **Special Instructions:** Do not chase above $3.80; if gap up beyond limit, reassess.
- **Rationale:** Fortress is running up ahead of a Sept 30 FDA decision for a key rare-disease drug [25]. Adding a small number of shares boosts our exposure to this event-driven upside while keeping risk controlled. The $3.80 limit is just above the last close ($3.71) to ensure execution if momentum continues. Stop remains at $2 to guard against a severe downturn on bad news.

3. Buy FDMT (4D Molecular Therapeutics) – *New position*
- **Action:** Buy
- **Ticker:** FDMT

- **Shares:** 2
- **Order Type:** Limit (DAY)
- **Limit Price:** $7.50
- **Intended Execution Date:** 2025-09-08
- **Stop-Loss:** $5.75 (initial stop for new position)
- **Special Instructions:** Limit $7.50 to account for 9/5 closing price ~$7.27 [33] ; if not filled due to a gap >3%, no chase – re-evaluate entry.
- **Rationale:** Establishing a stake in 4D Molecular after its positive trial news (zero inflammation in eye therapy study) [31] . The stock showed momentum (nearly +10% on 9/5) and could continue to rebound toward analysts' $25 target [32] . A $7.50 limit gets us in near recent prices without overpaying. Stop at $5.75 limits downside ~20% – below recent support (~$6) but above summer lows – reflecting higher volatility in this biotech.

(No change to ABEO and ATYR positions this week – thus no new buy orders for them. Existing stop-loss orders remain in place/adjusted as noted.)

Risk And Liquidity Checks

- **Post-Trade Portfolio Allocation:** After these moves, the portfolio will hold four stocks: ATYR (~51% of equity), ABEO (~26%), FDMT (~11%), FBIO (~9%), plus ~3% cash buffer. The largest position (ATYR) is about half the portfolio – an elevated concentration we are **monitoring carefully**. This weighting is justified short-term by a high-conviction catalyst, but we acknowledge it as a risk. No other single name exceeds ~30%. We have realized some gains and diversified slightly with the new FDMT position.
- **Cash After Trades:** Approximately **$3.9** will remain in cash (roughly 3% of the portfolio) for flexibility. We stayed within our budget – using only proceeds from the AXGN sale and existing cash to fund the FBIO and FDMT buys. No additional capital was added.
- **Stop-Loss Updates:** All holdings have stop orders in place or adjusted: ABEO at $6.20 (unchanged, ~10% below current), ATYR tightened to $4.60 (~18% below current), FBIO at $2.00 (wide due to binary risk), FDMT at $5.75 (~21% below entry). These levels were chosen based on technical support levels and risk tolerance, and they will be revisited regularly.

- **Liquidity and Execution:** Each planned trade is very small relative to each stock's average volume. For example, selling 2 AXGN shares vs. ~1.1M avg daily volume is negligible; buying 2 FDMT vs. ~0.7M daily volume is likewise inconsequential [40] . The limit orders are set near prevailing market prices, so we expect easy fills without significant slippage. No liquidity issues are anticipated. We avoided any OTC/pink-sheet names – all positions are NASDAQ-listed with adequate trading volume.

- **Compliance Check:** All actions comply with the stated constraints. We're trading full shares only and staying long-only. The new additions (FBIO, FDMT) are U.S. micro-caps in our biotech focus area. The portfolio remains within the micro/small-cap universe (aside from ATYR/AXGN growing above $300M, which we justified due to ongoing conviction and then addressed by exiting AXGN). We flagged the concentration in ATYR as a risk to watch. Stop losses are in place portfolio-wide. No margin or derivatives are used.

Monitoring Plan

We will monitor each holding closely, especially around known catalysts and risk events:

- **Abeona (ABEO):** Track commercialization progress of ZEVASKYN. We expect news on the **first patient dosing** (expected in Q3 2025) and initial sales updates [3] [4]. Any indications of uptake (or hurdles) will inform whether to add on strength or reduce risk. Also watch for additional gene therapy pipeline/licensing news (e.g., updates on the Beacon Therapeutics AAV deal [41]). Maintain stop and consider raising it once revenue ramps.

- **aTyr Pharma (ATYR):** The critical watch item is **Phase 3 trial results** for efzofitimod. We anticipate top-line data could emerge in late 2025; any guidance on timing from the company will be key. We will also monitor peer news in sarcoidosis and any partnership/buyout rumors (common for successful Phase 3 orphan drug developers). Given ATYR's size, general biotech sentiment and Nasdaq small-cap trends could impact it – index inclusion should help stability [13]. We'll adjust the stop higher if the stock appreciates meaningfully pre-data.

- **Fortress Biotech (FBIO):** The **Menkes disease drug PDUFA on Sept 30** is the main event. We will be vigilant in late September: if approval rumors or FDA documents leak, extreme volatility could occur. Our plan is to **potentially take profit on a pre-event run-up** if the stock surges well beyond our cost before the decision (to de-risk), or to hold a core through the decision if confidence remains high. If approval is granted, we'll assess the stock's jump vs. long-term value (Fortress could rally but sometimes sells the news). In case of a negative outcome, our stop at $2.00 is in place (though we acknowledge gap risk). We'll also watch progress of Fortress's other programs and any insider buying or financing moves, as the company has a history of opportunistic raises.

- **4D Molecular (FDMT):** Monitor for **follow-up data presentations or analyst coverage** after the recent positive trial news. Any additional efficacy data or expansion of the trial could drive the next leg up. We'll track sector news: gene therapy stocks can move as a group on regulatory or safety headlines. Also, FDMT's cash burn and quarterly updates will be reviewed – if cash drops too fast or a capital raise looms, we may exit before dilution. Our stop is set, and we'll consider taking partial profits if the stock approaches the mid-teens (where it traded earlier this year before a setback).

- **Macro/Market:** We remain cognizant of broader market conditions. Small-cap biotechs are sensitive to interest rate changes and risk sentiment [42]. Any signs of market stress (e.g., a spike in volatility or biotech sell-off) may prompt us to tighten stops or lighten positions to protect the portfolio's gains (currently +32% vs. start). We'll also keep an eye on the **XBI biotech index** as a barometer for our sector.

We plan at least **daily check-ins** on prices and news feeds for each holding, with intra-day alerts for critical news (FDA announcements, trial results). Given the high-risk nature of micro-caps, we stand ready to act swiftly if any thesis changes or if stops are hit. The monitoring plan is to ensure we capture upside from catalysts while strictly limiting downside per our risk rules.

Thesis Review Summary

In summary, our portfolio is positioning for strong **catalyst-driven growth** while tightening risk controls. We have exited Axogen to redeploy into more immediate opportunities, namely Fortress Biotech (upcoming FDA decision) and 4D Molecular Therapeutics (post-positive data momentum). Our core holdings Abeona and aTyr remain high-conviction to **outperform the market** – Abeona is transitioning to commercial stage with a funded runway [5], and aTyr is on the cusp of Phase 3 results that could be transformative [11]. These two form the backbone of our thesis, supported by solid fundamentals and news flow. Fortress and 4DMT add tactical spice: one a near-term binary event play, the other a beaten-down innovator with new validation. Overall, the portfolio is **up ~32% in 9 weeks**, far ahead of the S&P 500's ~4.5% in the same period, and we aim to build on that lead [43]. The coming week (Week 10) will be about catalyst anticipation and risk management – ensuring we have the right exposure levels as we head into late September's event calendar. We will review the thesis on each name continuously and remain ready to adjust if the story changes.

Confirm Cash And Constraints

After executing the above orders, our cash balance will be approximately **$3.90**. We have **not used margin or leverage** at any point – all positions are fully funded by portfolio cash. All trades were placed in compliance with stated constraints: full-share orders, only long equity positions, focusing on micro-cap U.S. stocks (all tickers listed on NASDAQ/NYSE). The largest positions (ATYR, ABEO) have grown above $300M market cap due to price appreciation, which we have allowed given their strong prospects, while still prioritizing micro-cap ideas for new additions (FBIO, FDMT both ~$100–300M). Risk measures are in place: every holding has a stop-loss order, position sizing is deliberate (no single name over ~50% of the portfolio), and overall portfolio risk is aligned with our aggressive but controlled strategy. We will continue to enforce budget discipline and risk limits strictly. The portfolio is **well-positioned** for the next phase, with cash for flexibility, defined exit levels, and exposure to high-upside catalysts – all within the framework of generating superior risk-adjusted returns over our 6-month horizon.

---

[1] [2] [3] [4] [5] [6] [41] Abeona Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates
https://finviz.com/news/140468/abeona-therapeutics-reports-second-quarter-2025-financial-results-and-corporate-updates

[7] [8] ABEO - Abeona Therapeutics Inc Stock Price and Quote
https://finviz.com/quote.ashx?t=ABEO

[9] [10] [13] [14] [15] [18] ATyr Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 | MarketScreener
https://www.marketscreener.com/news/atyr-pharma-inc-reports-earnings-results-for-the-second-quarter-and-six-months-ended-june-30-2025-ce7c5edcdd8cf725

[11] [12] 2 Small-Cap Biotech Stocks Well Positioned for a | SwingTradeBot.com
https://swingtradebot.com/news-articles/22083852-2-smallcap-biotech-stocks-well-positioned

[16] aTyr Pharma, Inc Latest Stock Price, Analysis, News and Trading Ideas
https://stocktwits.com/symbol/ATYR

17 aTyr Pharma, Inc. (ATYR) Stock Price, Quote, News & Analysis
https://seekingalpha.com/symbol/ATYR

19 AXGN - Axogen Inc Latest Stock News & Market Updates
https://www.stocktitan.net/news/AXGN/

20 Axogen stock falls after FDA extends review timeline for nerve graft
https://www.investing.com/news/stock-market-news/axogen-stock-falls-after-fda-extends-review-timeline-for-nerve-graft-93CH-4209243

21 Axogen Shares Fall Premarket as FDA Extends Avance Review
https://www.morningstar.com/news/dow-jones/202508252441/axogen-shares-fall-premarket-as-fda-extends-avance-review

22 Why Axogen Stock, Up 76% Over The Last Two Months ... - Bundle
https://www.bundle.app/en/finance/why-axogen-stock-up-76-over-the-last-two-months-just-plummeted-C1E2565F-C696-4C2E-A2C3-4784AEB4BFFE

23 Current Quote :: Axogen, Inc. (AXGN)
https://ir.axogeninc.com/current-quote?__hstc=163339491.2f3f33a24b44870ec4a577029c49e44b.1752192000055.1752192000056.1752192000057.1&__hssc=163339491.1.1752192000058&__hsfp=2324370431

24 Fortress Biotech, Inc. (FBIO) Stock Historical Prices & Data
https://finance.yahoo.com/quote/FBIO/history/

25 26 Fortress Biotech Soars 13.73% on Menkes Disease Treatment Hopes
https://www.ainvest.com/news/fortress-biotech-soars-13-73-menkes-disease-treatment-hopes-2509/

27 Tonix Pharmaceuticals Reports Second Quarter 2025 Financial ...
https://ir.tonixpharma.com/news-events/press-releases/detail/1584/tonix-pharmaceuticals-reports-second-quarter-2025-financial

28 Nano-Cap Tonix Pharmaceuticals Secures Large US Department of ...
https://finance.yahoo.com/news/nano-cap-tonix-pharmaceuticals-secures-150724887.html

29 Fortress Biotech, Inc. (FBIO) Stock Price, News, Quote & History
https://finance.yahoo.com/quote/FBIO/

30 Fortress Biotech (FBIO) Stock Forecast: Analyst Ratings, Predictions ...
https://public.com/stocks/fbio/forecast-price-target

31 32 Top Biotech Penny Stocks to Watch Out for in September 2025
https://stockstotrade.com/top-biotech-stocks/

33 40 4D Molecular Therapeutics, Inc. Common Stock (FDMT) Historical ...
https://www.nasdaq.com/market-activity/stocks/fdmt/historical

34 38 Omeros (OMER) Market Cap & Net Worth - Stock Analysis
https://stockanalysis.com/stocks/omer/market-cap/

35 Omeros (OMER) Financials 2025 - Income Statement and Balance ...
https://www.marketbeat.com/stocks/NASDAQ/OMER/financials/

36 Why Omeros Corporation's (OMER) Stock Is Up 5.64% | AAII
https://www.aaii.com/investingideas/article/306945-why-omeros-corporation8217s-omer-stock-is-up-564

37 Omeros Corporation (OMER) Stock Historical Prices & Data
https://finance.yahoo.com/quote/OMER/history/

[39] 4D Molecular Therapeutics - FDMT - Stock Price Today - Zacks
https://www.zacks.com/stock/quote/FDMT

[42] A Small-Cap Catalyst Play with Russell Lift and Clinical Milestones ...
https://www.ainvest.com/news/xenon-pharmaceuticals-xene-small-cap-catalyst-play-russell-lift-clinical-milestones-2506/

[43] Stock Data - Abeona Therapeutics Inc. (ABEO)
https://investors.abeonatherapeutics.com/stock-data